Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px

Organisation › Details

VelosBio Inc.

https://www.velosbio.com

VelosBio Inc. is a privately held, US-based, near-term clinical-stage biopharmaceutical company focused on novel cancer targets. The company was founded in 2017 and has an investor syndicate that includes Arix Bioscience, Decheng Capital, Pappas Capital, Sofinnova Ventures, and Takeda Ventures. *

	Start	2017-01-01 established
	Group	Merck (US) (MSD) (Group)
	Industry	antibody-drug conjugate (ADC)
	Industry 2	VLS-101 ADC targeting ROR1 (VelosBio)
	Person	Johnson, David (Dave) (VelosBio 201810 CEO before Acerta Pharma + Roche + Immunex + Millennium + Gloucester)

	Region	San Diego, CA
	Country	United States (USA)
	Street	3210 Merryfield Row
	City	92121 San Diego, CA
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Arix Bioscience plc. (10/1/18). "Press Release: Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio". London.

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Merck (US) (MSD) (Group)

[1] Owkin. (12/19/23). "Press Release: Owkin Enters Collaboration Agreement with MSD to Develop AI-powered Diagnostics for Cancer"....
[2] Merck & Co., Inc.. (11/21/23). "Press Release: Merck to Acquire Caraway Therapeutics, Inc.". Rahway, NJ & Cambridge, MA....
[3] Merck & Co., Inc.. (10/19/23). "Press Release: Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs". Basking Ridge, NJ & Rahway, NJ....
[4] AiCuris Anti-infective Cures AG. (8/23/23). "Press Release: AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of Prevymis (letermovir) in Second Indication". Wuppertal....
[5] Anavo Therapeutics B.V.. (5/2/23). "Press Release: Anavo Therapeutics Extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic". Leiden & Heidelberg....
[6] Proxygen GmbH. (4/5/23). "Press Release: Proxygen Announces Collaboration and License Agreement with MSD". Vienna....
[7] Merck & Co., Inc.. (12/21/22). "Press Release: Lynparza (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer". Rahway, NJ....
[8] Novartis AG. (9/1/22). "Press Release: Novartis Appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., Steps Down from the Executive Committee of Novartis". Basel....
[9] Moderna, Inc.. (4/27/22). "Press Release: Arpa Garay Joins Moderna as Chief Commercial Officer". Cambridge, MA....
[10] Catalym GmbH. (5/4/21). "Press Release: Catalym Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]